Bayer’s sevabertinib picks up a second-line indication for HER2-mutated disease, joining Boehringer’s zongertinib on the US ...

While this panel has grown in recent years, many experts believe additional biomarkers should also be incorporated as ...

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive ...

Andamertinib showed promising efficacy in NSCLC patients with EGFR exon 20 mutations, achieving a 42.7% ORR in the 240-mg cohort.

The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...

The FDA has granted an accelerated approval for the use of sevabertinib (Hyrnuo; Bayer) in patients with nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 ( ERBB2) tyrosine kinase ...

The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with ...

Discover why Rigel Pharma (RIGL) is a contrarian biotech BUY with surging revenues, strong drug sales, and 20-30% upside ...

The FDA has granted an accelerated approval to sevabertinib (Hyrnuo) for the treatment of adult patients with previously ...

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

The Food and Drug Administration granted accelerated approval on Wednesday for a new drug developed by researchers at the ...

At the European Society of Medical Oncology Congress in October 2025 in Berlin, Germany, researchers shared results from the BEACON study, which is the first real-world look at how integrin beta-6 ...